Company intelligence / Profile preview

江苏贵琼药业

Taizhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

江苏贵琼药业成立于2024年，是一家专注于小核酸药物研发与产业化的生物医药企业。公司拥有一支深耕核酸领域多年的创始人团队，并建立了先进的小核酸药物研发平台。其首个核心产品为1类新药舒欣瑞纳注射液，该药物针对临床上缺乏有效治疗手段的肿瘤厌食-恶病质综合征，通过调控致病因子表达来改善患者的食欲、睡眠与生存质量，目前已获批IND并即将开展临床试验。此外，公司在泰州投资超5亿元建设研发中心与核酸药物产业化基地，一期预计于2026年底建成，致力于成为核酸药物领域的领先企业。

Therapeutic areas: Oncology
Modalities: Small interfering RNABiologic
Industry: Biotech

Partnerships

江苏核泰生物有限公司

Beyond the preview

Go deeper on 江苏贵琼药业.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 江苏贵琼药业.

Explore the full profile